Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $91.56, for a total value of $274,680.00. Following the transaction, the insider now directly owns 197,583 shares in the company, valued at approximately $18,090,699.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Clovis Oncology, Inc. (CLVS) opened at 78.50 on Monday. The stock’s market capitalization is $3.50 billion. Clovis Oncology, Inc. has a 1-year low of $14.62 and a 1-year high of $99.45. The company has a 50 day moving average price of $87.51 and a 200-day moving average price of $66.24.
Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.27) by $0.02. The company had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter in the prior year, the company posted ($2.07) EPS. Clovis Oncology’s revenue for the quarter was down 32.5% compared to the same quarter last year. On average, equities research analysts forecast that Clovis Oncology, Inc. will post ($5.96) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Clovis Oncology, Inc. (NASDAQ:CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://stocknewstimes.com/2017/08/07/clovis-oncology-inc-nasdaqclvs-insider-sells-274680-00-in-stock-updated-updated.html.
CLVS has been the topic of several research analyst reports. ValuEngine lowered Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, May 19th. BidaskClub raised Clovis Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of Clovis Oncology in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. initiated coverage on Clovis Oncology in a research report on Friday, June 23rd. They set a “market perform” rating on the stock. Finally, Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Monday, July 31st. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $81.59.
A number of institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares during the last quarter. First Mercantile Trust Co. purchased a new position in shares of Clovis Oncology during the first quarter worth about $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 100 shares during the last quarter. 90.67% of the stock is owned by hedge funds and other institutional investors.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
